PLUTO (PAZOPANIB VERSUS PACLITAXEL IN RELAPSED UROTHELIAL TUMOURS)
Research type
Research Study
Full title
A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.
IRAS ID
84421
Contact name
Robert (Rob) Jones
Contact email
Eudract number
2011-001841-34
ISRCTN Number
ISRCTN73030316
Research summary
There are different types of urothelial cancer (cancer of the bladder, urethra, ureter or renal pelvis). The most common type in the UK is transitional cell carcinoma or TCC. Patients with advanced urothelial cancer are treated with chemotherapy. Although initial chemotherapy works well in most patients, the disease grows back in over 90% of patients who then go on to die of their disease. When a patient??s disease grows back after initial chemotherapy the outcome is poor and survival tends to be under 12 months. These patients may be treated with further chemotherapy such as a paclitaxel. Unfortunately the outcome for these patients is very poor even with this chemotherapy. Pazopanib is a new drug which has been licensed for the treatment of kidney cancer, however early trials have also shown it to be effective in the treatment of urothelial cancer as well. The purpose of this study is to compare pazopanib and paclitaxel in patients who have failed initial chemotherapy for urothelial cancer. We will investigate if patients who receive pazopanib live longer than those who receive the paclitaxel chemotherapy.
REC name
West of Scotland REC 1
REC reference
11/WS/0090
Date of REC Opinion
7 Nov 2011
REC opinion
Favourable Opinion